Format

Send to

Choose Destination
Am J Clin Pathol. 2016 Oct;146(4):408-22. doi: 10.1093/ajcp/aqw131.

Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

Author information

1
From the Department of Laboratory Hematology, Hôpital Maisonneuve-Rosemont, Universté De Montréal, Montréal, Quebec, Canada lbusque.hmr@ssss.gouv.qc.ca vikas.gupta@uhn.ca.
2
Department of Pathology, University Health Network Department of Laboratory Medicine and Pathobiology.
3
Fusion MD Medical Science Network, Montréal, Quebec, Canada.
4
Department of Hematology and Transfusional Medicine, Centre Hospitalier De L'Université De Montréal, Montréal, Quebec, Canada.
5
Department of Medicine, Hematology and Thromboembolism, McMaster University, Hamilton, Ontario, Canada.
6
From the Department of Laboratory Hematology, Hôpital Maisonneuve-Rosemont, Universté De Montréal, Montréal, Quebec, Canada.
7
Division of Hematology, Jewish General Hospital, Montréal, Quebec, Canada.
8
Division of Hematology, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
9
Department of Oncology, McGill University, Montréal, Quebec, Canada.
10
Pathology & Laboratory Medicine and Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
11
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada lbusque.hmr@ssss.gouv.qc.ca vikas.gupta@uhn.ca.

Abstract

OBJECTIVES:

To standardize diagnostic investigations for myeloproliferative neoplasms (MPNs) to increase homogeneity in patient care and to streamline diagnostic approaches in the most efficient and cost-effective manner.

METHODS:

The development of Canadian expert consensus recommendations for the diagnosis of MPNs began with a review of the following: clinical evidence, daily practice, existing treatment guidelines, and availability of diagnostic tools. Each group member was assigned a specific topic, which they discussed with the entire group during several consensus meetings.

RESULTS:

This document provides the Canadian MPN group's recommendations, proposed diagnostic algorithms, and background evidence upon which decisions were made.

CONCLUSIONS:

Standardization of diagnostic investigations will increase homogeneity in patient care and provide a foundation for future clinical research in this rapidly evolving therapeutic area. Streamlining diagnostic approaches in the most efficient and cost-effective manner will also result in significant cost saving for the health care system.

KEYWORDS:

BCR-ABL negative; CALR; Essential thrombocythemia; JAK2 V617F; MPL; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera

PMID:
27686169
DOI:
10.1093/ajcp/aqw131
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center